BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success

Group 1: Financial Performance - BridgeBio Pharma reported a total revenue of $502.1 million for the full year 2025, driven by the commercial success of its flagship product, Attruby [1] - In Q4 2025, Attruby generated $146 million in net product revenue, reflecting a 35% increase over Q3 [1] - The company experienced a net loss of $724.9 million for the year, but expects cash burn to stabilize and decrease as Attruby's margins expand [4] Group 2: Product Development and Clinical Milestones - BridgeBio achieved three positive Phase 3 readouts in late 2025 for Encaleret, BBP-418, and Infigratinib, positioning the company to potentially have six approved medicines by the end of its first decade [2] - New Drug Applications (NDAs) for Encaleret and BBP-418 are expected in H1 2026, with US launches targeted for late 2026 or early 2027 [2] Group 3: Market Position and Competitive Landscape - Attruby's near-complete stabilization of transthyretin serves as a key clinical differentiator that should protect its market share against potential generic competitors for tafamidis [4]